Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs Quanta Services Inc (PWR) Price & Performance

Adaptive Biotechnologies CorpTrade
Quanta Services IncTrade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs Quanta Services Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while Quanta Services Inc trades at $679 (market cap $100.82B). The key difference: Quanta Services Inc is far larger — about 25× Adaptive Biotechnologies Corp's market cap, and Quanta Services Inc pays a 0.07% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.

ADPTPWR
Market Cap
$4.04B$100.82B
Sector
HealthIndustrials
52-Week High
$25.45$785.24
52-Week Low
$12.30$372.50
Enterprise Value
$4.10B$106.91B
Dividend Yield
0.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.

The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.

Quanta Services Inc

PWR trades at $677.91, up 2.58% today, with strong technical momentum above key support at $664. The company demonstrates robust fundamentals with Q2 2026 EPS of $4.24 beating expectations by 28%, revenue growth accelerating to $28.48B in 2025, and a record backlog supporting raised 2026 guidance. Analyst sentiment remains overwhelmingly positive with 72% buy ratings and a $809.75 consensus target.

PWR offers compelling growth exposure to infrastructure demand, particularly in power and data centers, but faces valuation concerns with a P/E of 76.7x. Near-term risks include execution on large projects and macroeconomic sensitivity, while institutional accumulation and strong cash flow generation support the bullish thesis.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About Quanta Services Inc

Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.

Read more on PWR